FDA has postponed a deadline for deciding whether to revoke approval of the drug Avastin for treatment of advanced breast cancer, the drug's manufacturer said on Friday, the New York Times' "Prescriptions" reports. The agency extended its review period until Dec. 17 because the manufacturer -- Roche unit Genentech -- submitted new data on Avastin, which works by blocking blood to tumors...
More...
Linear Mode
